Vical Joins Forces With Astellas On CMV Vaccine
This article was originally published in PharmAsia News
Executive Summary
Vaccine-focused biotech Vical Inc. announced July 14 that it has inked a global licensing agreement with Japan's Astellas Pharma Inc. to develop and commercialize the biotech's cytomegalovirus (CMV) vaccine, TransVax
You may also be interested in...
Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors
Astellas Pharma is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.
Astellas Steps Tentatively Into Global Vaccines, Following Path Of Japanese Competitors
Astellas Pharma Inc. is making forays into the vaccines segment, with the support of development firm ClearPath Development Company to accelerate the process.
Deals Of The Week: Merck/Simcere, Pfizer/Hisun, MedImmune/WuXi
The growing importance of emerging markets will be a primary discussion point Sept. 17-19 at Elsevier’s Pharmaceutical Strategic Alliances conference in New York